Grant: Engage Grants Program
University of Saskatchewan
$25,000.00
Evaluating efficacy of phage-based treatment for neonatal scours in piglets
EF 2014-15
Résumé
With an increase in the number of pathogenic bacteria developing resistance to multiple antibiotics, alternative technologies are needed to address this problem. One promising technology is the use of all-natural bacteriophage-based treatments that are effective against both antibiotic sensitive and antibiotic resistant organisms. Natura Biologics Inc., a young Canadian biotechnology company, has developed such a treatment for neonatal scours, a disease prevalent in young piglets. The effectiveness of the product has been demonstrated in the laboratory and its ability to prevent/treat the disease in piglets will be evaluated at the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) for their ability to protect against infections with E.coli in pigs. VIDO-InterVac is a global leader in infectious disease research and vaccine development for both human and animal vaccines. Several livestock vaccines have been developed at VIDO-InterVac, including a scours vaccines for cattle. Here, we want to establish a research partnership between VIDO-InterVac and Natura to evaluate the potential of bacteriophages for the treatment of E.coli K88 infections in swine.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
462650-2014
Name nom
Gerdts, Volker
Department département
Veterinary Microbiology
Organization id
16
Institution établissement
University of Saskatchewan
Province en
Saskatchewan
Province fr
Saskatchewan
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
102
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal management (animal diseases, breeding)
Area of application fr
Gestion des animaux (maladies animales, reproduction)
Research subject code
5201
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Bacteriology
Research subject fr
Bactériologie
Partie
1
Nb partie
1
Application title
Evaluating efficacy of phage-based treatment for neonatal scours in piglets
Keyword
NSERC
Application summary
With an increase in the number of pathogenic bacteria developing resistance to multiple antibiotics, alternative technologies are needed to address this problem. One promising technology is the use of all-natural bacteriophage-based treatments that are effective against both antibiotic sensitive and antibiotic resistant organisms. Natura Biologics Inc., a young Canadian biotechnology company, has developed such a treatment for neonatal scours, a disease prevalent in young piglets. The effectiveness of the product has been demonstrated in the laboratory and its ability to prevent/treat the disease in piglets will be evaluated at the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) for their ability to protect against infections with E.coli in pigs. VIDO-InterVac is a global leader in infectious disease research and vaccine development for both human and animal vaccines. Several livestock vaccines have been developed at VIDO-InterVac, including a scours vaccines for cattle. Here, we want to establish a research partnership between VIDO-InterVac and Natura to evaluate the potential of bacteriophages for the treatment of E.coli K88 infections in swine.